ContraFect Corp (CFRXQ)

Currency in USD
0.001
0.000(0.00%)
Closed·
CFRXQ Scorecard
Full Analysis
Stock generally trades with low price volatility
Trading near 52-week Low
CFRXQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0010.001
52 wk Range
0.0010.140
Key Statistics
Prev. Close
0.001
Open
0.001
Day's Range
0.001-0.001
52 wk Range
0.001-0.14
Volume
-
Average Volume (3m)
2.47K
1-Year Change
-90%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CFRXQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

ContraFect Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

ContraFect Corp Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Compare CFRXQ to Peers and Sector

Metrics to compare
CFRXQ
Peers
Sector
Relationship
P/E Ratio
0.0x−3.5x−0.5x
PEG Ratio
0.00−0.060.00
Price/Book
0.0x2.1x2.6x
Price / LTM Sales
0.0x10.0x3.3x
Upside (Analyst Target)
0.0%183.7%43.5%
Fair Value Upside
Unlock1.2%6.9%Unlock

Earnings

Latest Release
Nov 14, 2023
EPS / Forecast
-0.50 / -0.66
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CFRXQ Income Statement

FAQ

What Stock Exchange Does ContraFect Corp Trade On?

ContraFect Corp is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for ContraFect Corp?

The stock symbol for ContraFect Corp is "CFRXQ."

What Is the ContraFect Corp Market Cap?

As of today, ContraFect Corp market cap is 10.70K.

What Is ContraFect Corp's Earnings Per Share (TTM)?

The ContraFect Corp EPS (TTM) is -5.58.

From a Technical Analysis Perspective, Is CFRXQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ContraFect Corp Stock Split?

ContraFect Corp has split 2 times.

How Many Employees Does ContraFect Corp Have?

ContraFect Corp has 23 employees.

What is the current trading status of ContraFect Corp (CFRXQ)?

As of 07 Aug 2025, ContraFect Corp (CFRXQ) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.